The three main players in the obesity drug space -- VIVUS (VVUS), Arena Pharmaceuticals (ARNA), and Orexigen Therapeutics (NASDAQ: OREX) -- are prepared to brave the market's reaction and release their Q3 results.
VIVUS, in fact, already reported its results before the market opened this morning, and sales from its flagship drug Qsymia fell short of expectations. Shares plunged 25% on this news, and investors are wondering if Qsymia realistically has the potential to reach blockbuster status.
Although VIVUS' obesity drug often takes the spotlight, the company actually has another FDA-approved drug in its portfolio. In the following video, health care analysts Max Macaluso and David Williamson discuss what this drug is and whether it might be able to surpass Qsymia's sales in the future.
